Hong L Wang

7238715, Jul 3, 2007

Sep 30, 2004

10/957426

Kevin J. Tracey - Old Greenwich CT, US
Hong Wang - Havertown PA, US

The Feinstein Institute for Medical Research - Manhasset NY

A01N 43/40

514334, 514332, 514277, 514183

A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2. 2. 2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

7273872, Sep 25, 2007

Dec 5, 2003

10/729427

Kevin J. Tracey - Old Greenwich CT, US
Hong Wang - Havertown PA, US

The Feinstein Institute for Medical Research - Manhasset NY

A01N 43/42

514278, 514277, 514183, 514 1

Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor.

7785808, Aug 31, 2010

Mar 15, 2007

11/724605

Kevin J. Tracey - Old Greenwich CT, US
Hong Wang - Havertown PA, US

The Feinstein Institute for Medical Research - Manhasset NY

G01N 33/567
G01N 33/53

435 721, 435 71, 435 72, 435 724, 5303871

A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2. 2. 2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

7803816, Sep 28, 2010

Sep 25, 2006

11/526523

Steven Joseph Berthel - Mendham Township NJ, US
Shawn David Erickson - Leonia NJ, US
Nader Fotouhi - Basking Ridge NJ, US
Robert Francis Kester - West Orange NJ, US
Kyungjin Kim - Livingston NJ, US
Steven Gregory Mischke - Florham Park NJ, US
Yimin Qian - Wayne NJ, US
Kshitij Chhabilbhai Thakkar - Clifton NJ, US
Jefferson Wright Tilley - North Caldwell NJ, US
Hong Wang - Nutley NJ, US

Hoffmann-La Roche Inc. - Nutley NJ

A61K 31/454
C07D 403/02

514322, 546199

Provided herein are compounds of the formula (I):.

20100256341, Oct 7, 2010

Jun 18, 2010

12/818347

Kevin J. Tracey - Old Greenwich CT, US
Hong Wang - Havertown PA, US

C07K 16/00

53038822, 5303891

A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

20110166148, Jul 7, 2011

Mar 16, 2010

12/724888

Kevin J. Tracey - Old Greenwich CT, US
Hong Wang - Havertown PA, US

The Feinstein Institute for Medical Research - Manhasset NY

A61K 31/4985
A61K 31/438
A61K 31/444
A61K 31/439
A61K 31/505
A61K 31/46
A61P 1/18

514249, 514278, 514332, 514305, 514257, 514248, 514299

A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.

20110245286, Oct 6, 2011

Feb 1, 2011

13/019053

KEVIN J. TRACEY - OLD GREENWICH CT, US
HONG WANG - HAVERTOWN PA, US

THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH - MANHASSET NY

A61K 31/439
A61K 31/444
A61P 29/00

514278, 514334, 514305, 514304

Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Additionally, methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Additionally, methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic.

20110288083, Nov 24, 2011

May 19, 2011

13/111769

Timothy CARDOZO - New York NY, US
Hong WANG - New York NY, US
David Ron - Cambridge, GB

NEW YORK UNIVERSITY - New York NY

A61K 31/536
C12Q 1/48
A61K 31/519
A61K 31/496
A61K 31/4166
A61K 31/4245
A61K 31/433
A61K 31/24
A61K 31/428
A61K 31/225
C07D 487/04
C07D 417/14
C07D 403/06
C07D 413/12
C07D 285/135
C07C 69/76
C07D 277/62
C07C 69/34
A61P 35/00
A61P 25/28
A61P 9/10
A61P 25/00
A61P 3/04
A61P 37/00
A61P 25/16
A61P 19/02
A61P 37/06
A61P 1/00
G06G 7/60
C40B 30/02

5142305, 506 8, 435 15, 5142593, 51425402, 514389, 514364, 514363, 514534, 514367, 514548, 544281, 544369, 5483121, 548125, 548139, 560 61, 548180, 560194, 544 73, 703 11

The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK. The present invention further relates to compounds that can be used for inhibition of PERK, for example human PERK, and methods related to treatment of PERK-mediated diseases.